Answers are grounded in this paper and cite their sources.
The PAOLA-1/ENGOT-ov25 phase 3 trial is a first line treatment study for advanced ovarian cancer which showed that the maximum benefit of the PARP inhibitor olaparib plus bevacizumab maintenance is observed in patients with Homologous Recombination Deficient (HRD) tumors. Using PAOLA-1 data, we report a retrospective clinical evaluation of SeqOne HRD solution based on low-coverage and cost-effective whole genome sequencing (WGS).
No takes yet. Share an insight, caveat, or question.
Boidot et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: